Paul Barr, MD of University of Rochester, discusses how promising ibrutinib is as a first line treatment for older patients with CLL and comorbidities at the 58th ASH Annual Meeting in San Diego, CA.
Ibrutinib Promising As First-Line Treatment in Older Patients with CLL
